Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia

Science Translational Medicine

Volumn 8, Issue 335, 2016, Pages

  Cao, Lishuang ^a   McDonne, Aoibhinn ^a   Nitzsche, Anja ^a   Alexandrou, Aristos ^a   Saintot, Pierre Philippe ^a   Loucif, Alexandre J C ^a   Brown, Adam R ^a   Young, Gareth ^a   Mis, Malgorzata ^b   Randal, Andrew ^c   Waxman, Stephen G ^d   Stanley, Philip ^a   Kirby, Simon ^a   Tarabar, Sanela ^e   Gutteridge, Alex ^a   Butt, Richard ^a   McKernan, Ruth M ^a   Whiting, Paul ^a   Ali, Zahid ^a   Bilsland, James ^a   Stevensl, Edward B ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PF 05089771; PLACEBO; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; DIPHENYL ETHER DERIVATIVE; PF-05089771; SCN9A PROTEIN, HUMAN; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; ERYTHROMELALGIA; EXPLORATORY RESEARCH; FEMALE; GENE MUTATION; HUMAN; IN VITRO STUDY; MALE; MULTICENTER STUDY; NERVE CELL EXCITABILITY; NERVE POTENTIAL; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCN9A GENE; SENSORY NERVE CELL; SINGLE DRUG DOSE; THERMAL STIMULATION; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MUTATION; PAIN; RANDOMIZED CONTROLLED TRIAL;

ADULT; ERYTHROMELALGIA; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MUTATION; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PAIN; PHENYL ETHERS; SENSORY RECEPTOR CELLS; SULFONAMIDES;

EID: 84964484494     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad7653     Document Type: Article

References (28)

1. J. P. H. Drenth, S. G. Waxman, Mutations in sodium channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117, 3603-3609 (2007).
2. S. D. Dib-Hajj, Y. Yang, J. A. Black, S. G. Waxman, The Nav1.7 sodium channel: From molecule to man. Nat. Rev. Neurosci. 14, 49-62 (2013).
3. D. L. H. Bennett, C. G. Woods, Painful and painless channelopathies. Lancet Neurol. 13, 587-599 (2014).
4. A. McDonnell, B. Schulman, Z. Ali, S. D. Dib-Hajj, F. Brock, S. Cobain, T. Mainka, J. Vollert, S. Tarabar, S. G. Waxman, Inherited erythromelalgia due to mutations in SCN9A: Natural history, clinical phenotype and somatosensory profile. Brain 139(Pt. 4), 1052-1065 (2016).
5. T. R. Cummins, S. D. Dib-Hajj, S. G. Waxman, Electrophysiological properties of mutant NaV1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24, 8232-8236 (2004).
6. M.-T. Wu, P.-Y. Huang, C.-T. Yen, C.-C. Chen, M.-J. Lee, A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLOS One 8, e55212 (2013).
7. M. Estacion, Y. Yang, S. D. Dib-Hajj, L. Tyrrell, Z. Lin, Y. Yang, S. G. Waxman, A new Nav1. 7 mutation in an erythromelalgia patient. Biochem. Biophys. Res. Commun. 432, 99-104 (2013).
8. M. Eberhart, J. Nakajima, A. B. Klinger, C Neacsu, K. Hühne, A. O. O'Reilly, A. M. Kist, A. K. Lampe, K. Fischer, J. Gibson, C. Nau, A. Winterpacht, A. Lampert, Inherited pain: Sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J. Biol. Chem. 289, 1971-1980 (2014).
9. T. Stadler, A. O. O'Reilly, A. Lampert, Erythromelalgia Mutation Q875E Stabilizes the Activated State of Sodium Channel Nav1. 7. J. Biol. Chem. 290, 6316-6325 (2015).
10. E. C. Emery, A. M. Habib, J. J. Cox, A. K. Nicholas, F. M. Gribble, C. G. Woods, F. Reimann, Novel SCN9A mutations underlying extreme pain phenotypes: Unexpected electrophysiological and clinical phenotype correlations. J. Neurosci. 35, 7674-7681 (2015).
11. J. W. Theile, B. W. Jarecki, B. W, A. D. Piekarz, T. R. Cummins, Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Nav|34 peptidemediated resurgent sodium currents. J. Physiol. 589, 597-608 (2011).
12. S. D. Dib-Hajj, J. S. Choi, L. J. Macala, L. Tyrrell, J. A. Black, T. R. Cummins, S. G. Waxman, Transfection of rat or mouse neurons by biolistics or electroporation. Nat. Protoc. 4, 1118-1126 (2009).
13. S. M. Chambers, Y. Qi, Y. Mica, L. Gabsang, X.-J. Zhang, L. Niu, J. Bilsland, L. Cao, E. Stevens, P. Whiting, S.-H. Shi, L. Studer, Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715-720 (2012).
14. G. T. Young, A. Gutteridge, H. D. E. Fox, A. L. Wilbrey, L. Cao, L. T. Cho, A. R. Brown, C. L. Benn, L. R. Kammonen, J. H. Friedman, M. Bictash, P. Whiting, J. G. Bilsland, E. B. Stevens, Characterizing human stem cell-derived sensory neurons at the single-cell level reveals their ion channel expression and utility in pain research. Mol. Ther. 22, 1530-1543 (2014).
15. M. Grskovic, A. Javaherian, B. Strulovici, G. Q. Daley, Induced pluripotent stem cells-Opportunities for disease modelling and drugdiscovery. Nat. Rev. Drug Discov. 10, 915-929 (2011).
16. J. McNeish, J. P. Gardner, B. J. Wainger, C. J. Woolf, K. Eggan, From dish to bedside: Lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell 17, 8-10 (2015).
17. T. Z. Fischer, E. S. Gilmore, M. Estacion, E. Eastman, S. Taylor, M. Melanson, S. D. Dib-Hajj, S. G. Waxman, A novel Nav1. 7 mutation producing carbamazepine responsive erythromelalgia. Ann Neurol. 65, 733-741 (2009).
18. Y. P. Goldberg, N. Price, R. Namdari, C J. Cohen, M. H. Lamers, C Winters, J. Price, C E. Young, H. Verschoof, R. Sherrington, S. N. Pimstone, M. R. Hayden, Treatment of Nav1. 7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain 153, 80-85 (2012).
19. Y. P. Goldberg, C. J. Cohen, R. Namdari, N. Price, J. A. Cadieux, C. Young, R. Sherrington, S. N. Pimstone, Letter to the Editor. Pain 155, 837-838 (2014).
20. D. V. Vasylyev, C. Han, P. Zhao, S. Dib-Hajj, S. G. Waxman, Dynamic-clamp analysis of wildtype human Nav1. 7 and erythromelalgia mutant channel L858H. J. Neurophysiol. 111, 1429-1443 (2014).
21. S. D. Dib Hajj, A. M. Rush, T. R. Cummins, F. M. Hisama, S. Novella, L. Tyrrell, L. Marshall, S. G. Waxman, Gain-of-function mutation in Nav1. 7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128, 1847-1854 (2005).
22. C. Han, S. D. Dib-Hajj, Z. Lin, Y. Li, E. M. Eastman, L. Tyrrell, X. Cao, Y. Yang, S. G. Waxman, Early and late-onset inherited erythromelalgia: Genotype-phenotype correlation. Brain 132, 1711-1722 (2009).
23. Y. Yang, S. D. Dib-Hajj, J. Zhang, Y. Zhang, L. Tyrrell, M. Estacion, S. G. Waxman, Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a NaV1. 7 mutant channel. Nat. Commun. 3, 1186 (2012).
24. K. Ørstavik, C. Weidner, R. Schmidit, M. Schmelz, H. Hilloges, E. Jørum, H. Handwerker, E. Torebjörk, Pathological C-fibres in patients with a chronic painful condition. Brain 126, 567-578 (2003).
25. O. Uyanik, C. Quiles, H. Bostock, S. D. Dib-Hajj, T. Fischer, L. Tyrrell, S. G. Waxman, J. Serra, Spontaneous impulse generation in C-nociceptors of familial erythromelalgia (FE) patients. Eur. J. Pain 11, S130-S293 (2007).
26. B. Namer, K. Ørstavik, R. Schmidt, I.-P. Kleggetveit, C. Weidner, C. Mørk, M. S. Kvernebo, K. Knut, H. Salter, T. H. Carr, M. Segerdahl, H. Quiding, S. G. Waxman, H. O. Handwerker, H. E. Torebjörk, E. Jørum, M. Schmelz, Specific changes in conduction velocity recovery cycles of single nociceptors in an erythromelalgia patient with the I848T gain-of-function mutation of Nav1. 7. Pain 156, 1637-1646 (2015).
27. J. J. Michiels, R. H. Te Morsche, J. B. Jansen, J. P. Drenth, Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1. 7. Arch. Neurol. 62, 1587-1590 (2005).
28. ClinicalTrials.gov [Internet]. Identifier: NCT02215252 A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN). Available from: https://clinicaltrials.gov/ct2/show/